跳转至内容
Merck
CN
  • Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease.

Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease.

Molecular brain (2020-03-20)
Yumi Yamamoto, Katsutoshi Kojima, Daisuke Taura, Masakatsu Sone, Kazuo Washida, Naohiro Egawa, Takayuki Kondo, Eiko N Minakawa, Kayoko Tsukita, Takako Enami, Hidekazu Tomimoto, Toshiki Mizuno, Raj N Kalaria, Nobuya Inagaki, Ryosuke Takahashi, Mariko Harada-Shiba, Masafumi Ihara, Haruhisa Inoue
摘要

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is one of the most common forms of hereditary cerebral small vessel diseases and is caused by mutations in NOTCH3. Our group has previously reported incorporation of NOTCH3 extracellular domain (N3ECD) in the CADASIL-specific granular osmiophilic materials and increase of PDGFRβ immunoreactivity in CADASIL postmortem brains. Here, we aimed to establish an in vitro model of CADASIL, which can recapitulate those CADASIL phenotypes, using induced pluripotent stem cells (iPSCs). We have refined a differentiation protocol of endothelial cells to obtain mature mural cells (MCs) with their characteristic properties. iPSCs from three CADASIL patients with p.Arg182Cys, p.Arg141Cys and p.Cys106Arg mutations were differentiated into MCs and their functional and molecular profiles were compared. The differentiated CADASIL MCs recapitulated pathogenic changes reported previously: increased PDGFRβ and abnormal structure/distribution of filamentous actin network, as well as N3ECD/LTBP-1/HtrA1-immunopositive deposits. Migration rate of CADASIL MCs was enhanced but suppressed by knockdown of NOTCH3 or PDGFRB. CADASIL MCs showed altered reactivity to PDGF-BB. Patient-derived MCs can recapitulate CADASIL pathology and are therefore useful in understanding the pathogenesis and developing potential treatment strategies.

材料
货号
品牌
产品描述

Sigma-Aldrich
DAPT, ≥98% (HPLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting human NOTCH3